• 744 Citations
  • 16 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 18 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Waldenstrom Macroglobulinemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Dexamethasone Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidemiology Medicine & Life Sciences
Thalidomide Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma

Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M. H., Posner, G., Ralston, S., Zagadailov, E., Ba-Mancini, A. & Rifkin, R., Jan 1 2019, In : Clinical therapeutics.

Research output: Contribution to journalArticle

Multiple Myeloma
Costs and Cost Analysis
Subcutaneous Infusions

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 othersBerdeja, J. G., Feb 1 2019, In : Blood cancer journal. 9, 2, 17.

Research output: Contribution to journalArticle

Open Access
Multiple Myeloma
Anti-Idiotypic Antibodies
Maximum Tolerated Dose
Pharmaceutical Preparations

AlternativeOutpatientChemotherapy scheduling method to improve patient service quality and nurse satisfaction

Huang, Y. L., Bryce, A. H., Culbertson, T., Connor, S. L., Looker, S. A., Altman, K. M., Collins, J. G., Stellner, W., Mc Williams, R. R., Moreno Aspitia, A., Ailawadhi, S. & Mesa, R. A., Feb 1 2018, In : Journal of Oncology Practice. 14, 2, p. e82-e91

Research output: Contribution to journalArticle

Drug Therapy
Nursing Staff

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Ailawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J., Gharibo, M., Sher, T., Bojanini, L., Kirby, M. & Chanan Khan, A. A., Jan 1 2018, (Accepted/In press) In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Maximum Tolerated Dose
Clinical Trials, Phase I